Clinical Characteristics of Cryopyrin‐Associated Periodic Syndrome and Long‐Term Real‐World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey
Arthritis & Rheumatology · 2024
DOI: 10.1002/art.42808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Takayuki Miyamoto und 59 weiteren Autor:innen. Beteiligte Einrichtung: Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Cryopyrin-Associated Periodic Syndromes, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Ministry of Health, Labor, and Welfare of Japan, Japan Agency for Medical Research and Development, MEXT/JSPS KAKENHI.
Abstract (Originalsprache)
Objective
We assess the clinical characteristics of patients with cryopyrin‐associated periodic syndrome (CAPS) in Japan and evaluate the real‐world efficacy and safety of interleukin‐1 (IL‐1) inhibitors, primarily canakinumab.
Methods
Clinical information was collected retrospectively, and serum concentrations of canakinumab and cytokines were analyzed.
Results
A total of 101 patients were included, with 86 and 15 carrying heterozygous germline and somatic mosaic mutations, respectively. We identified 39 mutation types, and the common CAPS‐associated symptoms corresponded with those in previous reports. Six patients (5.9% of all patients) died, with four of the deaths caused by CAPS‐associated symptoms. Notably, 73.7% of patients (100%, 79.6%, and 44.4% of familial cold autoinflammatory syndrome, Muckle–Wells syndrome, and chronic infantile neurological cutaneous articular syndrome/neonatal onset multisystem inflammatory disease, respectively) achieved complete remission with canakinumab, and early therapeutic intervention was associated with better auditory outcomes. In some patients, canakinumab treatment stabilized the progression of epiphysial overgrowth and improved height gain, visual acuity, and renal function. However, 23.7% of patients did not achieve inflammatory remission with crucial deterioration of organ damage, with two dying while receiving high‐dose canakinumab treatment. Serological analysis of canakinumab and cytokine concentrations revealed that the poor response was not related to canakinumab shortage. Four inflammatory nonremitters developed inflammatory bowel disease (IBD)—unclassified during canakinumab treatment. Dual biologic therapy with canakinumab and anti–tumor necrosis factor‐α agents was effective for IBD– and CAPS‐associated symptoms not resolved by canakinumab monotherapy.
Conclusion
This study provides one of the largest epidemiologic data sets for CAPS. Although early initiation of anti–IL‐1 treatment with canakinumab is beneficial for improving disease prognosis, some patients do not achieve remission despite a high serum concentration of canakinumab. Moreover, IBD may develop in CAPS after canakinumab treatment. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Kyoto University, Kyoto, Japan.
- Kagoshima University Hospital, Kagoshima, Japan.
- Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
- Gifu University, Gifu, Japan.
- Hiroshima University, Hiroshima, Japan.
- Tokyo Women's Medical University Hospital, Tokyo, Japan.
ORCID-Profile: Takayuki Miyamoto, Kazushi Izawa, Yuichi Yamasaki, Takako Miyamae, Masaki Shimizu, Yuichi Maeda, Satoshi Sato, Hiroyuki Wakiguchi, Masaaki Mori, Koremasa Hayama, Naomi Iwata
Förderung
- Ministry of Health, Labor, and Welfare of Japan
- Japan Agency for Medical Research and Development
- MEXT/JSPS KAKENHI
- AMED
- Japan Society for the Promotion of Science
Zitieren
APA
Miyamoto, T., Izawa, K., Masui, S., Yamazaki, A., Yamasaki, Y., Matsubayashi, T., Shiraki, M., Ohnishi, H., Yasumura, J., Kawabe, T., Miyamae, T., Matsubara, T., Arakawa, N., Ishige, T., Takizawa, T., Shimbo, A., Shimizu, M., Kimura, N., Maeda, Y., …, & Iwata, N. (2024). Clinical Characteristics of Cryopyrin‐Associated Periodic Syndrome and Long‐Term Real‐World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey. Arthritis & Rheumatology. https://doi.org/10.1002/art.42808
Vancouver
Miyamoto T, Izawa K, Masui S, Yamazaki A, Yamasaki Y, Matsubayashi T, et al. Clinical Characteristics of Cryopyrin‐Associated Periodic Syndrome and Long‐Term Real‐World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey. Arthritis & Rheumatology. 2024. doi:10.1002/art.42808
BibTeX
@article{Miyamoto2024,
author = {Miyamoto, Takayuki and Izawa, Kazushi and Masui, Sho and Yamazaki, Atsue and Yamasaki, Yuichi and Matsubayashi, Tadashi and Shiraki, Mayuka and Ohnishi, Hidenori and Yasumura, Junko and Kawabe, Tomohiro and Miyamae, Takako and Matsubara, Tomoyo and Arakawa, Naoya and Ishige, Takashi and Takizawa, Takumi and Shimbo, Asami and Shimizu, Masaki and Kimura, Naoki and Maeda, Yuichi and Maruyama, Yuta and Shigemura, Tomonari and Furuta, Junichi and Sato, Satoshi and Tanaka, Hiroshi and Izumikawa, Miharu and Yamamura, Masahiro and Hasegawa, Toshio and Kaneko, Hiroshi and Nakagishi, Yasuo and Nakano, Naoko and Iida, Yasunori and Nakamura, Tamaki and Wakiguchi, Hiroyuki and Hoshina, Takayuki and Kawai, Toshinao and Murakami, Kosaku and Akizuki, Shuji and Morinobu, Akio and Ohmura, Koichiro and Eguchi, Katsuhide and Sonoda, Motoshi and Ishimura, Masataka and Furuno, Kenji and Kashiwado, Momoko and Mori, Masaaki and Kawahata, Kimito and Hayama, Koremasa and Shimoyama, Kumiko and Sasaki, Natsuko and Ito, Taisuke and Umebayashi, Hiroaki and Omori, Tae and Nakamichi, Seiko and Dohmoto, Tomotsune and Hasegawa, Yasuyuki and Kawashima, Hisashi and Watanabe, Shojiro and Taguchi, Yuichiro and Nakaseko, Haruna and Iwata, Naomi},
title = {Clinical Characteristics of Cryopyrin‐Associated Periodic Syndrome and Long‐Term Real‐World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey},
journal = {Arthritis & Rheumatology},
year = {2024},
doi = {10.1002/art.42808}
}
EUVIMED